Carr-Gottstein Foods Co
Carr-Gottstein Foods Co was paid $666K by Medicaid between Jan 2018 and Feb 2022, across 30 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
EAGLE RIVER, AK 99577
Next to other Pharmacy providers in Alaska
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,410 | $189K | |
| 2019 | 2,634 | $194K | |
| 2020 | 1,790 | $118K | |
| 2021 | 2,191 | $149K | |
| 2022 | 150 | $16K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 1,148 | 1,097 | $210K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 1,011 | 931 | $202K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 793 | 719 | $173K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 1,805 | 1,504 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 24 | 24 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 191 | 139 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 120 | 116 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 906 | 748 | $7K |
| 80053 | Comprehensive metabolic panel | 1.0% | 706 | 638 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 565 | 488 | $5K |
| 87631 | <1% | 26 | 26 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 137 | 133 | $3K |
18 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 261 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 200 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 98 | $2K |
| 84484 | <1% | 238 | $2K | |
| 81001 | <1% | 600 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $1K |
| 80076 | <1% | 103 | $715.48 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 56 | $661.68 |
| 81025 | <1% | 92 | $617.33 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 39 | $519.78 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 15 | $480.15 |
| 71045 | Radiologic examination, chest; single view | <1% | 27 | $267.23 |
| 84600 | <1% | 15 | $261.15 | |
| 81003 | <1% | 94 | $198.33 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $148.80 |
| 83690 | <1% | 24 | $145.72 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13 | $12.01 |
| 36415 | Collection of venous blood by venipuncture | <1% | 827 | $1.62 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Albertsons LLC | Billings, MT | $108K |
| Albertsons LLC | Payette, ID | $97K |
| Albertsons LLC | Billings, MT | $41K |
| Albertsons LLC | Belgrade, MT | $37K |
| Albertsons LLC | Cut Bank, MT | $35K |
| Albertsons LLC | Great Falls, MT | $28K |
| Albertsons LLC | Nampa, ID | $14K |
| Albertsons LLC | Lewistown, MT | $13K |
| Albertsons LLC | Glendive, MT | $13K |
| Albertsons LLC | Great Falls, MT | $5K |
| Albertsons LLC | Livingston, MT | $4K |
| Albertsons LLC | Boise, ID | $316.16 |
| Albertsons LLC | Hamilton, MT | $286.95 |
| Albertsons LLC | Miles City, MT | $133.12 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.